Harvard Bioscience, Inc. (HBIO:NASDAQ) closed at $8.61 on November 4, 2026, down 0.69% on the day. The stock trades 5.4% below its 52-week high of $9.10 and 115.3% above its 52-week low of $4.00. Over the past year, it gained 45.9%. Harvard Bioscience, Inc. is part of the Capital Goods sector (Biotechnology: Laboratory Analytical Instruments).
In 252 trading sessions since November 4, 2025, HBIO closed higher on 124 days (49%). Its best day was April 15, 2026 (+16.90%) and its worst was May 12, 2026 (-20.91%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 1 time.
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands. In addition, the company offers spectrophotometers under the Libra,...
Find more stocks like HBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.